Trident Texofab Limited
Trident Texofab Limited Fundamental Analysis
Trident Texofab Limited (TTFL.BO) shows weak financial fundamentals with a PE ratio of 38.67, profit margin of 2.63%, and ROE of 7.61%. The company generates $1.2B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 42.5/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze TTFL.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakTTFL.BO struggles to generate sufficient returns from assets.
Valuation Score
WeakTTFL.BO trades at a premium to fair value.
Growth Score
ModerateTTFL.BO shows steady but slowing expansion.
Financial Health Score
ExcellentTTFL.BO maintains a strong and stable balance sheet.
Profitability Score
WeakTTFL.BO struggles to sustain strong margins.
Key Financial Metrics
Is TTFL.BO Expensive or Cheap?
P/E Ratio
TTFL.BO trades at 38.67 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, TTFL.BO's PEG of 11.12 indicates potential overvaluation.
Price to Book
The market values Trident Texofab Limited at 2.19 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 10.57 times EBITDA. This signals the market has high growth expectations.
How Well Does TTFL.BO Make Money?
Net Profit Margin
For every $100 in sales, Trident Texofab Limited keeps $2.63 as profit after all expenses.
Operating Margin
Core operations generate 5.27 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $7.61 in profit for every $100 of shareholder equity.
ROA
Trident Texofab Limited generates $2.84 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Trident Texofab Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Trident Texofab Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
TTFL.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
38.67
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
11.12
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.19
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.02
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.56
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.05
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.08
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.09
vs 25 benchmark
How TTFL.BO Stacks Against Its Sector Peers
| Metric | TTFL.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 38.67 | 26.71 | Worse (Expensive) |
| ROE | 7.61% | 1311.00% | Weak |
| Net Margin | 2.63% | -29317.00% (disorted) | Weak |
| Debt/Equity | 0.56 | 0.75 | Strong (Low Leverage) |
| Current Ratio | 2.05 | 10.53 | Strong Liquidity |
| ROA | 2.84% | -1537638.00% (disorted) | Weak |
TTFL.BO outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Trident Texofab Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Cyclical, Value, Infrastructure
EPS CAGR
N/A
Industry Style: Cyclical, Value, Infrastructure
FCF CAGR
N/A
Industry Style: Cyclical, Value, Infrastructure